These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38303927)

  • 1. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer.
    Yu M; Wu Y; Li Q; Hong W; Yang Y; Hu X; Yang Y; Lu T; Zhao X; Wei X
    Genes Dis; 2024 May; 11(3):100989. PubMed ID: 38303927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
    Wesolowski R; Sharma N; Reebel L; Rodal MB; Peck A; West BL; Marimuthu A; Severson P; Karlin DA; Dowlati A; Le MH; Coussens LM; Rugo HS
    Ther Adv Med Oncol; 2019; 11():1758835919854238. PubMed ID: 31258629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulation of colony-stimulating factor 1 receptor inhibitor pexidartinib on the senescence of mouse bone marrow-derived macrophages stimulated by lipopolysaccharide].
    Xiao TJ; Zhang J; Kang JB; Li L; Zhan JF; Wei Y; Tian A
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2023 Jun; 58(6):575-583. PubMed ID: 37272003
    [No Abstract]   [Full Text] [Related]  

  • 6. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
    Omstead AN; Paskewicz M; Gorbunova A; Zheng P; Salvitti MS; Mansoor R; Reed P; Ballengee S; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
    Carcinogenesis; 2022 Oct; 43(9):842-850. PubMed ID: 35552655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
    Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
    Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
    Holmgaard RB; Brachfeld A; Gasmi B; Jones DR; Mattar M; Doman T; Murphy M; Schaer D; Wolchok JD; Merghoub T
    Oncoimmunology; 2016 Jul; 5(7):e1151595. PubMed ID: 27622016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic Immunity.
    Barnwal A; Gaur V; Sengupta A; Tyagi W; Das S; Bhattacharyya J
    ACS Biomater Sci Eng; 2023 Nov; 9(11):6409-6424. PubMed ID: 37870457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
    Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
    Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The c.1085A>G Genetic Variant of
    Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
    Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
    [No Abstract]   [Full Text] [Related]  

  • 14. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
    Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
    Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
    Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
    Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
    Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
    Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.